Phase II evaluation of L-alanosine (NSC-153353) for patients with disseminated malignant melanoma.
作者信息
Creagan E T, Long H J, Ahmann D L, Green S J
出版信息
Am J Clin Oncol. 1984 Oct;7(5):543-4. doi: 10.1097/00000421-198410000-00030.
Abstract
The authors conducted a phase II study of L-alanosine in 39 patients (19 without prior chemotherapy) in advanced malignant melanoma. The intravenous dose was 250 mg/m2/days 1-3 repeated at 3-week intervals. There were two objective regressions (5%) in conjunction with generally transient and tolerable hematologic and gastrointestinal toxicity. L-alanosine as used in our study has limited activity against malignant melanoma.
摘要
相似文献
1
Phase II evaluation of L-alanosine (NSC-153353) for patients with disseminated malignant melanoma.
Am J Clin Oncol. 1984 Oct;7(5):543-4. doi: 10.1097/00000421-198410000-00030.
2
Phase II study of L-alanosine (NSC 153353) in patients with advanced breast cancer. A Southwest Oncology Group study.
Invest New Drugs. 1991 Feb;9(1):87-8. doi: 10.1007/BF00194553.
3
A phase II study of alanosine in advanced large bowel carcinoma.
Am J Clin Oncol. 1983 Apr;6(2):191-3. doi: 10.1097/00000421-198304000-00009.
4
Phase I study of L-alanosine (NSC 15353).
Cancer. 1983 Feb 1;51(3):378-80. doi: 10.1002/1097-0142(19830201)51:3<378::aid-cncr2820510303>3.0.co;2-i.
5
Phase II evaluation of oral idarubicin (4-demethoxydaunorubicin) in patients with disseminated malignant melanoma.口服伊达比星（4-去甲氧基柔红霉素）治疗播散性恶性黑色素瘤患者的II期评估。
Cancer Treat Rep. 1986 Jul;70(7):911-2.
6
The treatment of acute leukemia with continuous infusion L-Alanosine.持续输注L-丙氨酸治疗急性白血病。
Invest New Drugs. 1983;1(3):249-51. doi: 10.1007/BF00208898.
7
Phase II studies of single-agent cimetidine and the combination N-phosphonacetyl-L-aspartate (NSC-224131) plus L-alanosine (NSC-153353) in advanced malignant melanoma.单药西咪替丁以及N-膦酰乙酰-L-天冬氨酸（NSC-224131）联合L-丙氨酰谷氨酰胺（NSC-153353）用于晚期恶性黑色素瘤的II期研究。
J Clin Oncol. 1987 Jul;5(7):1078-82. doi: 10.1200/JCO.1987.5.7.1078.
8
Phase II study of an aziridinylbenzoquinone (AZQ) in disseminated malignant melanoma.
Cancer Treat Rep. 1982 Dec;66(12):2089-90.
9
Phase I study of L-alanosine using a daily x 3 schedule.
Cancer Treat Rep. 1982 Jan;66(1):73-6.
10
Phase II study of high-dose tamoxifen (NSC-180973) in patients with disseminated malignant melanoma.高剂量他莫昔芬（NSC-180973）治疗播散性恶性黑色素瘤患者的II期研究。
Cancer. 1982 Apr 1;49(7):1353-4. doi: 10.1002/1097-0142(19820401)49:7<1353::aid-cncr2820490707>3.0.co;2-4.
引用本文的文献
1
Role of SLC7A11/xCT in Ovarian Cancer.SLC7A11/xCT 在卵巢癌中的作用。
Int J Mol Sci. 2024 Jan 2;25(1):587. doi: 10.3390/ijms25010587.
2
Targeting tumors that lack methylthioadenosine phosphorylase (MTAP) activity: current strategies.针对缺乏甲基硫腺苷磷酸化酶（MTAP）活性的肿瘤：当前策略。
Cancer Biol Ther. 2011 Apr 1;11(7):627-32. doi: 10.4161/cbt.11.7.14948.
3
A phase II multicenter study of L-alanosine, a potent inhibitor of adenine biosynthesis, in patients with MTAP-deficient cancer.一项关于L-丙氨酸（一种腺嘌呤生物合成的强效抑制剂）在MTAP缺陷型癌症患者中的II期多中心研究。
Invest New Drugs. 2009 Feb;27(1):75-81. doi: 10.1007/s10637-008-9160-1. Epub 2008 Jul 11.
4
Phase II study of L-alanosine (NSC 153353) in patients with advanced breast cancer. A Southwest Oncology Group study.
Invest New Drugs. 1991 Feb;9(1):87-8. doi: 10.1007/BF00194553.
Zotero 插件